SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Boston Scientific Corp – ‘8-K’ for 3/1/21

On:  Monday, 3/1/21, at 4:15pm ET   ·   For:  3/1/21   ·   Accession #:  1104659-21-29993   ·   File #:  1-11083

Previous ‘8-K’:  ‘8-K’ on / for 2/3/21   ·   Next:  ‘8-K’ on / for 3/3/21   ·   Latest:  ‘8-K’ on 5/11/21 for 5/6/21

Magnifying glass tilted right emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/01/21  Boston Scientific Corp            8-K:8,9     3/01/21   11:241K                                   Toppan Merrill/FA

Current Report   —   Form 8-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     34K 
 7: R1          Cover                                               HTML     53K 
 9: XML         IDEA XML File -- Filing Summary                      XML     12K 
 6: XML         XBRL Instance -- tm218230d1_8k_htm                   XML     21K 
 8: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 3: EX-101.DEF  XBRL Definitions -- bsx-20210301_def                 XML     75K 
 4: EX-101.LAB  XBRL Labels -- bsx-20210301_lab                      XML    104K 
 5: EX-101.PRE  XBRL Presentations -- bsx-20210301_pre               XML     72K 
 2: EX-101.SCH  XBRL Schema -- bsx-20210301                          XSD     14K 
10: JSON        XBRL Instance as JSON Data -- MetaLinks               27±    36K 
11: ZIP         XBRL Zipped Folder -- 0001104659-21-029993-xbrl      Zip     15K 


‘8-K’   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 iX:   C:   C:   C:   C:   C:   C:   C:   C:   C: 
 i 0000885725  i false 0000885725 2021-03-01 2021-03-01 0000885725 us-gaap:CommonStockMember 2021-03-01 2021-03-01 0000885725 bsx:SeniorNoteDue2027Member 2021-03-01 2021-03-01 0000885725 bsx:A550MCPSSeriesAMember 2021-03-01 2021-03-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

     

 

FORM  i 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

     

 

Date of Report (Date of earliest event reported):  i March 1, 2021

 

 i BOSTON SCIENTIFIC CORPORATION

(Exact name of registrant as specified in its charter)

 

 i Delaware    i 1-11083    i 04-2695240
(State or other jurisdiction of
incorporation)
  (Commission File Number)   (IRS Employer Identification No.)

 

 i 300 Boston Scientific Way,  i Marlborough,  i Massachusetts    i 01752-1234
(Address of principal executive offices)   (Zip Code)

 

( i 508)  i 683-4000

(Registrant's telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 i  Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 i  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 i  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 i  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
 i Common Stock, $0.01 par value per share    i BSX    i New York Stock Exchange
 i 0.625% Senior Notes due 2027    i BSX27    i New York Stock Exchange
 i 5.50% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share    i BSX PR A    i New York Stock Exchange

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company    i 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   

 

 

 C: 

 

 

 

ITEM 8.01 OTHER EVENTS.

 

Preventice Solutions, Inc. Acquisition

On March 1, 2021, Boston Scientific Corporation (the “Company”) completed its acquisition of Preventice Solutions, Inc. (“Preventice”). The transaction consists of an upfront cash payment of $925 million and up to an additional $300 million in a potential commercial milestone payment, or approximately $720 million upfront and $230 in a potential milestone payment, after accounting for the Company’s approximately 22 percent equity stake in Preventice prior to completing the acquisition. The Company previously announced entry into a definitive agreement to acquire Preventice on January 21, 2021. Preventice offers a full portfolio of mobile cardiac health solutions and services, ranging from ambulatory cardiac monitors – including short and long-term Holter monitors – to cardiac event monitors and mobile cardiac telemetry.

 

Specialty Pharmaceuticals Business Divestiture

On March 1, 2021, the Company completed the sale of the BTG Specialty Pharmaceuticals Business to Stark International Lux S.A.R.L., and SERB SAS, affiliates of SERB, a European specialty pharmaceutical group, for $800 million in cash. The sale follows the definitive agreement announced on December 1, 2020. Boston Scientific acquired the specialty pharmaceuticals business as part of its 2019 acquisition of BTG plc.

 

ITEM 9.01.FINANCIAL STATEMENTS AND EXHIBITS.

 

(d)  Exhibits

 

Exhibit No.   Description
104   Cover Page Interactive Data File – the cover page XBRL tags are embedded within the Inline XBRL document

 

 C: 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: March 1, 2021 BOSTON SCIENTIFIC CORPORATION
   
  By: /s/ Vance R. Brown
    Vance R. Brown
    Vice President and Chief Corporate Counsel  

 

 C: 

 

 

 

 

 C: 

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on / For Period end:3/1/21
1/21/218-K
12/1/204,  8-K
 List all Filings 
Top
Filing Submission 0001104659-21-029993   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2021 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Wed., May 12, 3:49:22.0pm ET